AI-Enabled Bundle of Sensors, Coaching Aids Type 2 Diabetes Outcomes
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 28, 2025 -- An artificial intelligence (AI)-enabled bundled system of sensors and coaching facilitates significant improvements in glycemic outcomes and de-escalation of glucose-lowering pharmacotherapy, according to a study published online Aug. 20 in NEJM Catalyst.
Kevin M. Pantalone, D.O., from the Cleveland Clinic, and colleagues assessed whether or not the Twin Precision Treatment AI-enabled bundled system of sensors and coaching system could help individuals -- with type 2 diabetes and managed in a primary care setting -- to achieve glycemic targets while concurrently de-escalating glucose-lowering medications. The analysis included 150 adults with type 2 diabetes and a body mass index ≥27 assigned to the bundled intervention system (100 individuals) or usual care (50 individuals).
The researchers found that the primary end point (hemoglobin A1c [HbA1c] <6.5 percent without glucose-lowering medications, except metformin, at 12 months) was achieved by 71.0 percent of intervention participants versus 2.4 percent of usual care participants. Additionally, significantly more intervention participants achieved or sustained the target ≥90 days prior to 12 months without glucose-lowering medications, except metformin (52.5 versus 2.8 percent). Mean changes in HbA1c levels (−1.3 versus −0.3 percent) and body weight (−8.6 versus −4.6 percent) were significantly greater with the intervention versus usual care. In a post hoc analysis, overall use of glucose-lowering pharmacotherapy decreased substantially with the intervention, but not usual care. The intervention group also showed significant improvement in quality-of-life and treatment satisfaction scores in exploratory analyses.
"By leveraging personalized lifestyle modifications to understand each patient’s unique metabolic profile, the tool enabled individuals to make impactful lifestyle choices," Pantalone said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Mortality Up for Children With Leukemia From Lowest SES Neighborhoods
THURSDAY, Aug. 28, 2025 -- Children with acute lymphoblastic leukemia (ALL) from the lowest socioeconomic status (SES) neighborhoods have an increased risk for mortality...
Shared, Sex-Specific Body Fat Patterns Linked to Cardiovascular Aging
WEDNESDAY, Aug. 27, 2025 -- Shared and sex-specific patterns of body fat are associated with changes in cardiovascular aging, according to a study published online Aug. 22 in the...
Elevated Circulating Trimethylamine N-Oxide Levels Linked to AAA Risk, Growth Rate
WEDNESDAY, Aug. 27, 2025 -- Elevated circulating trimethylamine N-oxide (TMAO) levels are associated with an increased risk for abdominal aortic aneurysms (AAA) and with the risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.